New obesity drug tested in 349 people – but not for weight loss yet

NCT ID NCT07313761

Ongoing Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests how two different injection versions of the experimental drug AMG 133 are absorbed by the body in 349 adults with overweight or obesity. Participants receive a single dose, and researchers measure drug levels and safety. The goal is not to treat obesity but to gather data for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Show contact details

Locations

Anaheim Clinical Trials

Anaheim, California, 92801-2658, United States
CenExel Collaborative Neuroscience Research, LLC Los Alamitos

Los Alamitos, California, 90720, United States
Clinical Pharmacology Of Miami, LLC

Miami, Florida, 33172-3161, United States
Ohio Clinical Trials, Inc.

Columbus, Ohio, 43212, United States